12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

OncoMed preclinical data

In mouse xenograft models of pancreatic cancer, demcizumab plus gemcitabine showed antitumor activity across a panel of patient-derived tumors and demcizumab delayed tumor recurrence following termination...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >